Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorderActive, not recruitingPhase 1 / Phase 22026-09-14NCT01012817

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Huntsman Cancer Institute/University of UtahSalt Lake CityUnited States249
Mayo Clinic Hospital in ArizonaPhoenixUnited States120
Mayo Clinic in ArizonaScottsdaleUnited States191
Mayo Clinic in FloridaJacksonvilleUnited States224
Mayo Clinic in RochesterRochesterUnited States687
Parkland Memorial HospitalDallasUnited States121
UC Comprehensive Cancer Center at Silver CrossNew LenoxUnited States136
UCHealth University of Colorado HospitalAuroraUnited States172
University of California Davis Comprehensive Cancer CenterSacramentoUnited States299
University of Chicago Comprehensive Cancer CenterChicagoUnited States273
University of Chicago Medicine-Orland ParkOrland ParkUnited States124
University of Kansas Clinical Research CenterFairwayUnited States81
University of Kentucky/Markey Cancer CenterLexingtonUnited States240
UPMC Hillman Cancer CenterPittsburghUnited States330
UT Southwestern/Simmons Cancer Center-DallasDallasUnited States273